A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy.
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Interferon alfacon-1 (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 16 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 14 Sep 2006 New trial record.